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Understanding patient preferences will help physicians to manage their patients’ 
disease most effectively and potentially ensure greater adherence to therapy. 
Further research is warranted to understand patient preferences quantitatively.
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Objectives: To quantify UK psoriasis patients’ tolerance for serious side-effect 
risks associated with biologic treatments relative to the value of symptom improve-
ments. MethOds: Members of a UK psoriasis patient organization were invited to 
complete an on-line conjoint-analysis survey which evaluated efficacy and safety 
features of biologic treatments for psoriasis. Patients’ trade-off preferences for 
improvements in the severity and coverage of psoriatic lesions were elicited, as well 
as treatment-related risks of tuberculosis (TB), serious infections, and lymphoma. 
The choice pattern observed in the data was used to estimate preference weights 
which indicated patients’ relative trade-off preferences among treatment outcomes.
Preference weights were used to derive maximum levels of side-effect risks that 
patients would accept for various improvements in psoriasis symptoms. The DLQI 
was used to assess the impact of psoriasis on patients’ quality of life. Results: A 
total of 159 people with a self-reported physician diagnosis of psoriasis completed 
the survey. Mean age was 39 years and most respondents reported having psoriasis 
for at least 5 years. Also, the mean DLQI score was 11. Respondents would accept up 
to 0.39% of treatment-related risks of lymphoma for reducing the area covered by a 
severe lesion from 25% to 10% of their torso, and up to 0.60% if lesions were on their 
arms or legs.For the same improvement in symptoms, respondents would accept up 
to a 2.3% risk of TB or 3.3% risk of serious infections if the lesions were on their torso, 
and a 3.6% risk of TB or 5.2% risk of serious infections if the lesions were on their arms 
and legs. cOnclusiOns: Psoriasis patients’ tolerance for side-effect risks varies with 
side-effect severity and location of lesions. Estimates of patients’ risk tolerance for 
serious side-effects indicate that patients value psoriasis symptom control further 
confirming that psoriasis has a significant effect on patients’ quality of life.
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Objectives: Atopic Dermatitis (AD) is a common skin condition, even in adults. 
On the contrary of quality of life questionnaires, the notion of individual burden 
associated with a disease has been introduced to determine the “disability” in 
the broadest sense. The aim of the current study was to develop and validate 
the Atopic dermatitis Burden Scale questionnaire for Adults (ABS-A) following 
Classical Test Theory method (CTT). MethOds: The questionnaire was developed 
by a working group composed of individuals with expertise in PRO development, 
dermatologists, and patients from patients’ association. Subsequently, this ques-
tionnaire was sent to 900 people with AD. ABS-A was refined via exploratory factor 
analysis (EFA). Internal consistency was determined by calculating the Cronbach’s 
alpha, concurrent validity by calculating the Spearman’s rank coefficient correla-
tion between ABS-A, SF-12 and Dermatology Life Quality Index (DLQI) question-
naires. Discriminant validity was analysed according to the severity degrees of AD 
assessed by the Patient Oriented SCORing index of AD questionnaire. Results: 
A total of 128 individuals filled out the ABS-A entirely and were then evaluated. 
68.8% of them were men and almost 50% of them were aged between 35 and 64 
years old. Based on the results of the EFA, 1 item was removed due to cross-loading 
on factors. Consequently, the questionnaire consisted of 18 items grouped into 
4 domains. ABS-A showed good internal coherence (Cronbach’s á: 0.89). ABS was 
significantly correlated to both components of the SF-12 (r(PCS)= -0.36, p< 0.0001; 
r(MCS)= -0.52 , p< 0.0001). A higher coefficient correlation has been found between 
ABS-A and DLQI (r= 0.78; p< 0.0001). Significant differences between severity 
degrees of AD have been shown. cOnclusiOns: These preliminary results 
suggest the validity of the ABS-A questionnaire. However, since recruitment of 
patients is not achieved, performing analyses of the other stages of CTT, and 
Confirmatory Factor analysis or Rash analysis are warranted. Comparison between 
both methods may be valuable.
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Objectives: The notion of individual burden, associated with the disease, has been 
introduced recently to determine the “disability” caused by the pathology in the 
broadest sense of the word (psychological-social-economic-physical). MethOds: 
The ABS questionnaire (Atopy Burden Score Q) consists of 19 items, structured 
around 5 components. It was distributed to a random sample of families consulting 
at the Necker Hospital, staying at the Avène Hydrotherapy Center, and members of 
the patient-association. The ABS was accompanied by SF12 and PGWBI, to confirm 
internal and external validation, and by the PO-SCORAD to assess the level of sever-
ity. Results: A total of 58 Q were considered evaluable. 51% of the AD children 
were girls. The PO-SCORAD established the level of severity of the AD: 14%, 50% and 
36% of children had mild, moderate or severe AD respectively. Internal-validity was 
measured by Cronbach’s alpha, which is equal to 0.81, reflecting a good homogeneity 
of the 19 items. The mean PGWBI score is 51.82±14.28. The score reflecting the most 
important deterioration is found among parents of children with severe atopy. In 
contrast, the scores associated with moderate and mild atopy are not correlated 
with severity. Families’ QoL, measured using the SF12, revealed no deterioration 
in the physical component. The ABS score is correlated with the scores of the Q 
little difference. cOnclusiOns: Using a sequence model of biologic therapies in 
psoriasis, first-line ustekinumab was found to be cost-effective in the treatment 
of moderate-to-severe psoriasis in Finland.
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Objectives: To calculate the Cost-Utility of unilateral pediatric Cochlear Implantation 
in Hungary. Parallel to that, we aim to provide an assessment of currently served cases 
and epidemiological demand. MethOds: Cost accounting of direct medical costs, 
from public purchaser perspective, covering medical resources sacrificed for unilateral 
implant in 1 year children, with a 60 year life expectancy. Cost-utility is calculated 
based on direct costs and QALY gain retrieved from literature, both to be discounted 
at 3% annually. Prevalence of eligible newborns to undergo Cochlear Implantation 
versus served cases is reported. Results: Draft estimation of total direct costs is 
12.26 million HUF (25,288 EUR) and when discounted it would be 7.3 million HUF 
(24,219 EUR). This is divided into 2.1% preoperative, 53.8% operative (including cost 
of implant) and 44% post operative. Based on health utility reported by Cheng, dis-
counted QALY gain ranges from 6.1 to 10.8 life years. Therefore, Cost-utility of uni-
lateral CI would range from 679,433 HUF (2,343 EUR) to 1,204,449 HUF (4,153 EUR) per 
discounted QALY gain. Currently in Hungary, about 90 cases are operated per year 
(0.1 % of crude birth rate). From 220 to 250 new cases, 2.5 to 3 times currently served, 
every year (0.24 – 0.37 % of crude birth rate), would be necessary for providing equal 
access to care. cOnclusiOns: This study provides an overview to Hungarian policy 
makers and other stakeholders about cost-utility, direct costs and estimated effect, 
and also of the possible full capacity of such costly intervention. Unilateral Cochlear 
Implantation appears to be reasonable if direct costs per QALY are compared to GDP 
in Hungary. Hungarian values are compared with international values.
SenSory SyStemS diSorderS – Patient-reported outcomes & Patient  
Preference Studies
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Objectives: Psoriasis is a chronic, systemic immune-mediated disorder char-
acterised by skin and often joint involvement affecting 2.3% of the Australian 
population. While psoriasis has traditionally been viewed as a non-serious skin 
condition, it is now recognised as a systemic inflammatory disease with a growing 
body of evidence linking the condition with a number of serious co-morbidities. 
The objective of this study was to determine the burden, in terms of disutility and 
resource use, that co-morbidities have on patients with psoriasis. MethOds: A 
large-scale, multi-centre, cross-sectional study of Australian adults with psoria-
sis was conducted during 2011. The survey contained 43 questions and focused 
primarily on comorbidity, health care resource use and the impact of psoriasis 
on disutility as assessed by EQ-5D. Results: A total of 330 patients responded 
to the survey. Three-quarters of respondents reported having at least two or 
more concomitant medical conditions, with only 8% reporting no comorbidities. 
Combined, joint-related conditions such as joint pain (46%) and psoriatic arthritis 
(28%) represented the largest proportion of medical comorbidities reported. The 
mean EQ-5D score for the cohort was 0.73. Utility decreased as the number of co-
morbidities increased, ranging from 0.88 for patients with no co-morbidities to 
0.36 for patients with 9 co-morbidities. Resource use and out of pocket expenses 
also increased with increasing number of co-morbidities. cOnclusiOns: This 
study highlights the co-morbid nature of psoriasis with most respondents report-
ing having two or more concomitant conditions. Furthermore, based on the mean 
EQ-5D health status score, psoriasis has a considerable impact on patient quality 
of life comparable with other chronic diseases.
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Objectives: To investigate qualitatively patient preferences for monitoring and 
treatment in the management of neovascular (wet) age-related macular degen-
eration (wAMD) in different countries. MethOds: The study involved 39 patients 
with wAMD from the UK (n= 9), Canada (n= 10), Germany (n= 10) and Japan (n= 10). 
Subjects participated in a 30-minute semi-structured telephone interview. Data 
were analysed to identify key themes and opinions. Results: Most (74%, n= 29) 
patients were aged ≥ 70 years, 28% (n= 11) required a caregiver to attend clinic visits, 
and 90% (n= 35) had comorbidities. Only 13% (n= 5) of patients were treatment-
naïve, 41% (n= 16) had received ≤ 1 year of therapy and 46% (n= 18) had received > 
1 year of therapy. Most (92%, n= 36) were currently or had previously been receiving 
ranibizumab; 8% (n= 3) were receiving or about to initiate therapy with aflibercept. 
Most patients (62%, n= 24) preferred monthly monitoring with treatment given as 
needed based on disease progression, 26% (n= 10) preferred bimonthly monitoring 
and fixed bimonthly dosing and 13% (n= 5) had no preference. Patients reported 
being very anxious about their sight and tended implicitly to trust their treat-
ing physician to decide on the most appropriate treatment; as a result, patients 
reported being highly adherent to therapy. Many patients reported appreciating 
the reassurance provided by frequent monitoring and were very satisfied with 
their current dosing regimen as chosen by their treating physician. cOnclusiOns: 
The results of this pilot, qualitative study suggest that most patients prefer 
frequent monitoring with dosing based on disease progression to treat their wAMD. 
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all 3 studies were analysed using latent growth models to generate intercepts and 
slopes of change across trials for each patient, irrespective of treatment. Slopes 
of change were correlated to examine how closely DLQI changes mirrored UAS7 
changes. Results: Results indicated that both measures showed large improve-
ments over the course of the trials: UAS7 and DLQI scores were high at the start 
of the study reflecting moderate-severe CSU/CIU (UAS7) and a very large effect on 
patient’s life (DLQI). Correlations between changes in DLQI and changes in UAS7 by 
study end were 0.88, 0.85, and 0.88, indicating high correspondence between the two 
measures. cOnclusiOns: These results suggest that collecting DLQI information 
in-clinic can provide an excellent indication of the weekly UAS7 score, and is more 
efficient for clinical practice routine in assessing CSU/CIU patients.
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Objectives: Some psoriasis patients also have psoriatic arthritis (PsA), which 
increases disease burden and further reduces quality-of-life (QoL). Our objective 
was to compare QoL of subjects with both psoriasis and PsA to those with psoriasis 
alone, and to evaluate improvement on etanercept (ETN) therapy in specific coun-
tries of Central and Eastern Europe, Latin America, and Asia where data are lim-
ited. MethOds: Patients with moderate/severe psoriasis were randomized to 50mg 
ETN QW (once weekly) or 50mg ETN BIW (twice weekly, weeks 1-12), followed by 50mg 
QW (weeks 13-24). The following post-hoc assessments were included: EuroQoL-5D 
(EQ-5D); Dermatology Quality of Life Index (DLQI); Functional Assessment of Chronic 
Illness Therapy (FACIT)-Fatigue; Hospital Anxiety and Depression Scale (HADS); 
Medical Outcomes Study (MOS)-Sleep; and Work Productivity and Activity Impairment 
(WPAI). Subjects with and without PsA were pooled across ETN groups for compari-
sons of changes in scores from baseline to week 24, which were based on independent 
sample t-tests. Results: Of 171 subjects analysed, 64 (37.4%) had PsA. Baseline demo-
graphic characteristics and QoL measures were similar in PsA and psoriasis-alone 
groups. EQ-5D scores improved significantly over time with ETN treatment in both 
subjects with and without PsA (P< 0.0001) with similar adjusted mean improvement 
in both groups after 24 weeks (0.2 vs 0.2; P= 0.6202). Improvement in EQ-5D greater 
than MID (change ≥ 0.05) at week 24 was observed in a greater proportion of PsA than 
psoriasis-alone subjects (74.6% vs 63.8%; P= 0.174). Significant improvements from 
baseline in both PsA and psoriasis-alone groups were also observed after 24 weeks in 
DLQI (both P< 0.0001), FACIT (both P< 0.01) and HADS anxiety (both P< 0.0001) scores. 
Improvements of other patient-reported outcomes were also observed at weeks 24 in 
both disease subgroups. cOnclusiOns: ETN in both dose regimens provided signifi-
cant improvement in QoL measures in subjects with moderate-to-severe psoriasis, 
regardless of the presence of PsA.
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Objectives: To assess the impact of etanercept (ETN) on quality-of-life (QoL) through 
24 weeks in patients with moderate/severe psoriasis in specific countries of Central 
and Eastern Europe, Latin America, and Asia where data are limited. MethOds: 
Patients with moderate/severe psoriasis were randomized to 50mg ETN QW (once 
weekly) or 50mg ETN BIW (twice weekly, weeks 1-12), followed by 50mg QW (weeks 
13-24). Patients completed the Dermatology Life Quality Index (DLQI) EuroQoL 5D (EQ-
5D), FACT-Fatigue, HADS Anxiety Score, Psoriasis Subject Satisfaction Questionnaire, 
and Work Productivity Activity Impairment (WPAI) at baseline and subsequent vis-
its. Results: Of 171 patients analysed, 85 were randomised to ETN BIW and 86 to ETN 
50 QW. Baseline DLQI scores were 14.8 in both treatment groups suggesting severe 
QoL impairment. Significant improvements in DLQI from baseline were observed 
at weeks 12 and 24 in both groups (all p< 0.0001); mean improvement at week 12 for 
ETN BIW was greater than for ETN QW (10.8 vs 8.4, p= 0.001), but was similar between 
groups at week 24 (11.0 vs 9.5, p= 0.063). EQ-5D utility was significantly improved 
from baseline in both groups at weeks 12 and 24 (all p< 0.0001), with mean improve-
ment significantly greater for the higher dose at both time-points (week 12: 0.3 vs. 
0.2, p= 0.029; week 24: 0.3 vs. 0.2, p= 0.027). Mean EQ-5D improvement at week 24 
was greater than MID (change ≥ 0.05) in a significantly greater proportion of patients 
receiving BIW than QW (77.1% vs 58.8%; p= 0.013). Improvements of other patient-
reported outcomes from baseline were observed at weeks 12 and 24 in both treat-
ment groups. cOnclusiOns: At baseline, patients had severely impaired QoL, and 
improvement in QoL was achieved with both ETN regimens. Improvements observed 
with ETN BIW were significantly greater than with ETN QW for both DLQI and EQ-5D 
utility at week 12, but only for EQ-5D at week 24.
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used, thus confirming external validity. The mean score calculated from the ABS 
is 48.17±18.36. The score increases with the severity of the AD. A statistically sig-
nificant difference is observed between the 3 severity-groups, i.e. mild, moderate 
and severe, with scores of 30.63, 42.55 and 62.62 respectively. cOnclusiOns: The 
internal and external validity of our Q were confirmed. ABS is correlated with the 
severity of AD. Hence, we have a short, easy-to-use, validated tool for assessing the 
burden imposed by atopy on families. Following cultural and linguistic validation, 
the ABS is now available in US English, Spanish, German and Italian.
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Objectives: The notion of individual burden, associated with the disease, has 
been introduced recently to determine the “disability” caused by the pathology in 
the broadest sense of the word (psychological-social-economic-physical). The aim 
of our study is to develop a specific questionnaire for assessing the burden on fami-
lies of children with HI. MethOds: A “Hemangioma Family Burden” questionnaire 
(HFB) consisting of 22 items, The score increases with the heaviness of the burden. It 
was distributed accompanied by 2 validated QoL questionnaires (SF12 and PGWBI) 
to obtain internal and external validation Results: A total of 58 evaluable Q were 
returned. One parent from each family described how they perceived the effects of 
the disease, which led to the creation of 6 severity groups, paired together for size 
reasons: “not-very-far-reaching” and “somew-hat-far-reaching”; “quite-far-reaching” 
and “far-reaching”; “very far-reaching” and “extremely far-reaching”. Internal validity 
was measured by Cronbach’s alpha, which is equal to 0.95, reflecting a good homoge-
neity of the 22 Q items. The mean scores of the physical and mental components are 
54.93±5.12 and 40.49±11.28 respectively. Hence, the HFB score is correlated with these 
2 components, thus confirming external validity. The mean score calculated from the 
HFB is 23.42±19.93. The score increases with the “severity score” of the parents. In 
fact, a statistically significant difference is observed between the 3 severity groups: 
5.28±6.8 for those reporting the smallest extent to 41.0±18.71 for those reporting the 
greatest extent, and 27.7±16.96 for a moderate extent. This confirms the sensitivity of 
the HFB cOnclusiOns: During the evaluation, internal and external validity were 
confirmed. The HFB is correlated with the extent felt by parents, a feeling deemed 
relevant because it is often the cause of consultation and demand for treatment. 
We now have an easy-to-use, validated IH tool for assessing the disability caused. 
Following cultural and linguistic validation, the HFB is now available in US English, 
Spanish, German and Italian.
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Objectives: Patient reported outcomes (PRO) are becoming useful tools for 
collecting and generating evidence for new medical products to show improve-
ments in health-related quality of life (HRQoL). Glaucoma is a chronic disease 
with high importance for patient HRQoL. The objective of this study was to review, 
analyze, and understand trends in the PRO instruments used in patients with 
Glaucoma. MethOds: A systematic literature search for Glaucoma trials with 
PROs endpoints was undertaken for the databases Pubmed, Embase, Biosis, Google 
Scholar and Cochrane. Data was collected for the study size, interventions, year, 
PRO instrument and results for PROs. Analysis for conducted to identify trends 
in commonly used PRO instruments and categorize results as positive, neutral or 
negative. Results: A total of 31 studies with a total of 9819 patients were identi-
fied. In these studies there were eleven different PROs instruments were identified 
that were Glaucoma health perception index, Glaucoma quality of life question-
naire (Glau-QoL), Glaucoma utility index, Impact of vision impairment, Low vision 
quality of life questionnaire, National eye institute visual function index-19 items, 
National eye institute visual function index-51 items, Nursing home vision quality 
of life questionnaire, Quality of life and visual function questionnaire, Vision core 
module 1, and Vision quality of life index. The most commonly used instruments 
were Impact of vision impairment (used in 7 studies) and Low vision quality of life 
questionnaire (used in 4 studies). cOnclusiOns: Patients with glaucoma have 
significant impairment in their QoL, hence collection of such data is important 
for new medical products. PRO instruments such as Impact of vision impairment 
and Low vision quality of life questionnaire have been commonly used to generate 
evidence to show which therapies improve patient QoL.
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Objectives: The UAS7 is a patient-reported measure of urticaria symptoms. Daily 
pruritus scores and number of hives are summed over 7 days for a weekly score. The 
DLQI was developed as a brief (10-item) patient-reported measure with one-week 
recall for routine clinical use to assess the psychosocial effects of skin disease. The 
objective of this analysis was to examine changes in the UAS7 with those of the 
DLQI to see if the DLQI could be used in a clinic visit in lieu of collecting one week 
of UAS7 diary data. MethOds: Data come from three pivotal, phase 3 clinical tri-
als investigating the effects of omalizumab for patients with refractory CSU/CIU 
(publication available elsewhere). DLQI data were collected at baseline and weeks 
4, 12, 24, and 40 (ASTERIA I and GLACIAL), and baseline and weeks 4, 12, and 28 
(ASTERIA II). UAS7 score was reported at baseline and every four weeks but data 
from the same weeks as the DLQI were used for these analyses. Pooled data from 
